Key Points
- Stabilize ABCs; begin targeted evaluation without delaying life-saving therapy.
- Use system-specific risk tools to guide testing and disposition.
- Order high-yield tests first; escalate imaging when indicated.
- Start evidence-based initial therapy and reassess frequently.
Algorithm
- Primary survey and vitals; IV access and monitors.
- Focused history/physical; identify red flags and likely etiologies.
- Order system-appropriate labs and imaging (see Investigations).
- Initiate guideline-based empiric therapy (see Pharmacology).
- Reassess response; arrange consultation and definitive management.
Clinical Synopsis & Reasoning
PE spans from incidental subsegmental disease to obstructive shock. Evaluate pretest probability (e.g., Wells/Geneva), apply age‑adjusted D‑dimer when appropriate, and use CTPA or V/Q based on renal function, pregnancy, and contrast tolerance. Risk‑stratify by RV dysfunction (echo/CT), biomarkers (troponin/BNP), and clinical instability to anticipate decompensation.
Treatment Strategy & Disposition
Anticoagulate promptly when suspicion is high and bleeding risk acceptable; choose DOACs for most stable patients, LMWH in cancer, and UFH if thrombolysis or procedures are possible. Consider systemic thrombolysis or catheter‑directed therapy for massive/submassive PE with deterioration. Assess for precipitating factors and plan duration of therapy (provoked 3 mo; unprovoked often extended). ICU for shock or advanced support; otherwise ward or outpatient pathways for low‑risk cases with reliable follow‑up.
Epidemiology / Risk Factors
- Risk factors vary by condition and patient profile
Investigations
| Test | Role / Rationale | Typical Findings | Notes |
|---|---|---|---|
| CBC | Baseline hematology | Abnormal counts | |
| BMP | Electrolytes/renal | Derangements |
Choosing Modality
| Scenario | Test |
|---|---|
| Normal chest radiograph in pregnancy | VQ preferred |
| Renal failure or iodinated allergy | VQ |
| Most adults with high suspicion | CTPA |
Pharmacology
| Medication | Mechanism | Onset | Role in Therapy | Limitations |
|---|---|---|---|---|
| Apixaban/Rivaroxaban | Direct factor Xa inhibition | Hours | First-line for most stable PE/DVT | Bleeding; interactions |
| Enoxaparin (LMWH) | Xa>IIa inhibition | Hours | Preferred initial AC in many stable cases; cancer VTE | Avoid severe renal failure |
| Unfractionated heparin (IV) | Antithrombin-mediated Xa/IIa inhibition | Immediate | Initial AC when lysis/cath possible or renal failure | Bleeding, HIT; monitor aPTT |
| Alteplase (systemic) | Plasminogen activation (fibrinolysis) | Rapid | Massive PE with shock or arrest | ICH/major bleed; contraindications |
| Catheter-directed therapy | Localized fibrinolysis/thrombectomy | Rapid | When systemic lysis high risk or ineffective | Bleeding; expertise required |
Prognosis / Complications
- Prognosis depends on severity, comorbidities, and timeliness of care
Patient Education / Counseling
- Explain red flags and when to seek emergent care.
- Reinforce medication adherence and follow-up plan.
Notes
Follow local PE pathways. Optimize CTPA timing and contrast bolus to reduce nondiagnostic scans.
References
Meet MDSteps: Smarter USMLE® Prep
MDSteps streamlines your study with an adaptive QBank (19,000+ high-yield MCQs across all 3 Steps), full CCS case simulations for Step 3 with live vitals and timed orders, and an exam-readiness dashboard that turns practice into insight. Build mastery by system and discipline, auto-create missed-item decks (Anki-exportable), and keep momentum with pacing guidance, trend lines, and suggested next sessions—so every block moves you closer to test-day confidence.
Compared with staples like UWorld and AMBOSS, MDSteps aims to give you the best of both worlds: exam-style practice that adapts to you, plus real-time analytics and a full CCS runner—all in one place. If you want targeted, exam-relevant reps with feedback that actually changes how you study, MDSteps is built for you.
Eplore MDSteps